CN1631877A - 马来酸桂哌齐特合成方法 - Google Patents
马来酸桂哌齐特合成方法 Download PDFInfo
- Publication number
- CN1631877A CN1631877A CN 200410009826 CN200410009826A CN1631877A CN 1631877 A CN1631877 A CN 1631877A CN 200410009826 CN200410009826 CN 200410009826 CN 200410009826 A CN200410009826 A CN 200410009826A CN 1631877 A CN1631877 A CN 1631877A
- Authority
- CN
- China
- Prior art keywords
- pyrrolidine
- synthetic method
- piperazine
- solvent
- cinepazide maleate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004201 cinepazide Drugs 0.000 title claims abstract description 35
- XSTJTOKYCAJVMJ-GVTSEVKNSA-N (z)-but-2-enedioic acid;(e)-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound OC(=O)\C=C/C(O)=O.COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 XSTJTOKYCAJVMJ-GVTSEVKNSA-N 0.000 title claims description 25
- 238000001308 synthesis method Methods 0.000 title 1
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 239000003513 alkali Substances 0.000 claims abstract description 14
- RCUDFXMNPQNBDU-VOTSOKGWSA-N cinepazide Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 RCUDFXMNPQNBDU-VOTSOKGWSA-N 0.000 claims abstract description 10
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 42
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 16
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 14
- LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical compound CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 claims description 13
- 238000010189 synthetic method Methods 0.000 claims description 13
- CWGPCQYKWJWNIU-UHFFFAOYSA-N [ClH](CCCCCCCCCCCCCCC)C1CCN2CCCC12 Chemical compound [ClH](CCCCCCCCCCCCCCC)C1CCN2CCCC12 CWGPCQYKWJWNIU-UHFFFAOYSA-N 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 5
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000001256 steam distillation Methods 0.000 claims description 4
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000011976 maleic acid Substances 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 10
- 229960004756 ethanol Drugs 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 229960000935 dehydrated alcohol Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- ZOIHAPJGSMQVCR-UHFFFAOYSA-N 5-(3-chloroprop-1-enyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(C=CCCl)=CC(OC)=C1OC ZOIHAPJGSMQVCR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 description 1
- HSABKEXHCNELRI-UHFFFAOYSA-N C=N.C=N.C=N.C=N.N1CCCC1 Chemical compound C=N.C=N.C=N.C=N.N1CCCC1 HSABKEXHCNELRI-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- YTFVRYKNXDADBI-UHFFFAOYSA-N O-Methylsinapic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- -1 cinnamoyl Chemical group 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410009826 CN1246310C (zh) | 2004-11-22 | 2004-11-22 | 马来酸桂哌齐特合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410009826 CN1246310C (zh) | 2004-11-22 | 2004-11-22 | 马来酸桂哌齐特合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1631877A true CN1631877A (zh) | 2005-06-29 |
CN1246310C CN1246310C (zh) | 2006-03-22 |
Family
ID=34845526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410009826 Active CN1246310C (zh) | 2004-11-22 | 2004-11-22 | 马来酸桂哌齐特合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1246310C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101979386A (zh) * | 2009-12-17 | 2011-02-23 | 海南康虹医药科技开发有限公司 | 制备桂哌齐特游离碱的方法 |
CN101708179B (zh) * | 2009-08-17 | 2011-06-01 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN101260092B (zh) * | 2008-04-14 | 2011-07-20 | 罗军 | 马来酸桂哌齐特的制备方法 |
CN101723918B (zh) * | 2008-10-24 | 2011-08-31 | 重庆医科大学医药研究所 | 马来酸桂哌齐特的制备工艺 |
CN102100695B (zh) * | 2009-08-17 | 2012-01-11 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN101591310B (zh) * | 2008-12-19 | 2012-03-21 | 王绍杰 | 一种马来酸桂哌齐特的制备方法 |
CN101602751B (zh) * | 2009-07-14 | 2012-07-25 | 上海医药工业研究院 | 一种马来酸桂哌齐特的制备方法 |
CN101531643B (zh) * | 2009-04-13 | 2012-11-14 | 上海理奥生物医药科技有限责任公司 | 一种改进的马来酸桂哌齐特的合成方法 |
CN103664830A (zh) * | 2012-09-05 | 2014-03-26 | 凌沛学 | 一种马来酸桂哌齐特改进的合成方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101565410B (zh) * | 2009-06-11 | 2011-06-29 | 北京紫萌同达科技有限公司 | 1-哌嗪乙酰基吡咯啶的一种制备方法 |
-
2004
- 2004-11-22 CN CN 200410009826 patent/CN1246310C/zh active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101260092B (zh) * | 2008-04-14 | 2011-07-20 | 罗军 | 马来酸桂哌齐特的制备方法 |
CN101723918B (zh) * | 2008-10-24 | 2011-08-31 | 重庆医科大学医药研究所 | 马来酸桂哌齐特的制备工艺 |
CN101591310B (zh) * | 2008-12-19 | 2012-03-21 | 王绍杰 | 一种马来酸桂哌齐特的制备方法 |
CN101531643B (zh) * | 2009-04-13 | 2012-11-14 | 上海理奥生物医药科技有限责任公司 | 一种改进的马来酸桂哌齐特的合成方法 |
CN101602751B (zh) * | 2009-07-14 | 2012-07-25 | 上海医药工业研究院 | 一种马来酸桂哌齐特的制备方法 |
CN101708179B (zh) * | 2009-08-17 | 2011-06-01 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN102100695B (zh) * | 2009-08-17 | 2012-01-11 | 北京四环制药有限公司 | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 |
CN101979386A (zh) * | 2009-12-17 | 2011-02-23 | 海南康虹医药科技开发有限公司 | 制备桂哌齐特游离碱的方法 |
CN103664830A (zh) * | 2012-09-05 | 2014-03-26 | 凌沛学 | 一种马来酸桂哌齐特改进的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1246310C (zh) | 2006-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1246310C (zh) | 马来酸桂哌齐特合成方法 | |
CN1551861A (zh) | 2,2,2-三氟乙醇的制造方法 | |
WO2011040766A2 (ko) | 1,4-이치환시클로헥산 유도체의 제조방법 | |
CN108530278A (zh) | 一种d,l-萘普生的制备方法 | |
CN1572761A (zh) | 二(三羟甲基丙烷)的制备方法 | |
CN1208297C (zh) | 联产甲萘酚和乙萘酚的制备方法 | |
CN111689876A (zh) | 一种盐酸二甲双胍蒸馏残渣的绿色回收工艺 | |
CN101591310B (zh) | 一种马来酸桂哌齐特的制备方法 | |
CN116425729A (zh) | 一种立他司特吗啉盐及其制备方法和应用 | |
CN1434809A (zh) | 高收率的高纯度蜜胺生产方法 | |
CN107513048B (zh) | 一种氘代沃替西汀氢溴酸盐的合成方法 | |
CN1086187C (zh) | 二环己基并18冠6的制备方法 | |
CN112225720A (zh) | 一种噻吩-2-乙酰氯的生产方法 | |
CN101508685B (zh) | 马来酸桂哌齐特的改进制备方法 | |
CN115043835B (zh) | 一种维立西呱的精制纯化方法 | |
RU2202538C2 (ru) | Способ получения 4-аминомасляной кислоты | |
KR100789557B1 (ko) | 디메틸 테레프탈레이트 제조공정의 부산물로부터메틸-4-포밀벤조에이트와 디메틸 테레프탈레이트의분리회수방법 | |
CN1740157A (zh) | N-取代基-4-哌啶醇的合成方法 | |
CN115536548B (zh) | 一种中间体环保合成方法 | |
CN114907348B (zh) | 一种4-氯-5-碘-7H-吡咯并[2,3-d]嘧啶的制备方法 | |
CN108329352A (zh) | 富马酸替诺福韦二吡呋酯的制备方法 | |
CN1502615A (zh) | 光学纯四氢呋喃-2-甲酸制备新工艺 | |
CN108191689A (zh) | 一种新型碘海醇节能环保的连续化制备方法 | |
CN101602751B (zh) | 一种马来酸桂哌齐特的制备方法 | |
JP4508670B2 (ja) | 高純度アダマンタントリオール類の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING SIHUAN PHARMACEUTICAL CO., LTD.; HAINAN S Free format text: FORMER OWNER: BEIJING SIHUAN PHARMACEUTICAL CO., LTD. Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081010 Address after: Beijing City, Tongzhou District Zhangjiawan Village East Qi Shanzhuang zip code: 101114 Co-patentee after: Hainan Sihuan Pharmaceutical Co.,Ltd Patentee after: Beijing four ring Pharmaceutical Co., Ltd. Co-patentee after: Hainan Sihuan Research Institute of Cardio-cerebral Vascular Medicine Co., Ltd. Address before: Beijing City, Tongzhou District Zhangjiawan Village East Qi Shanzhuang zip code: 101114 Patentee before: Beijing Sihuan Pharmaceutical Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Langfang four ring Gao Bo Pharmaceutical Co., Ltd. Assignor: Beijing Fourth Ring Pharmaceutical Co., Ltd.|Hainan Fourth Ring Pharmaceutical Co., Ltd.|Hainan Fourth Ring cardiovascular and cerebrovascular medicine Research Institute Co., Ltd. Contract record no.: 2011990001130 Denomination of invention: Synthesis method of cinepazide maleate Granted publication date: 20060322 License type: Exclusive License Open date: 20050629 Record date: 20111229 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20130422 Contract record no.: 2011990001130 Assignee after: Langfang high Bojing State Pharmaceutical Co. Ltd. Assignee before: Langfang four ring Gao Bo Pharmaceutical Co., Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190828 Address after: 101114 Beijing city Tongzhou District Zhangjiawan Town Qi Shanzhuang East Village Co-patentee after: Hainan Sihuan Pharmaceutical Co.,Ltd Patentee after: Beijing Sihuan Pharmaceutical Co., Ltd. Co-patentee after: Hainan Sihuan Research Institute of Cardio-cerebral Vascular Medicine Co., Ltd. Co-patentee after: Jilin Huikang Pharmaceutical Co., Ltd. Address before: 101114 East Qishanzhuang Village, Zhangjiawan, Tongzhou District, Beijing Co-patentee before: Hainan Sihuan Pharmaceutical Co.,Ltd Patentee before: Beijing Sihuan Pharmaceutical Co., Ltd. Co-patentee before: Hainan Sihuan Research Institute of Cardio-cerebral Vascular Medicine Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220218 Address after: 101114 Beijing city Tongzhou District Zhangjiawan Village East Shanzhuang Qi Patentee after: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee after: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee after: JILIN HUIKANG PHARMACEUTICAL Co.,Ltd. Address before: 101114 Beijing city Tongzhou District Zhangjiawan Town Qi Shanzhuang East Village Patentee before: BEIJING SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee before: HAINAN SIHUAN PHARMACEUTICAL Co.,Ltd. Patentee before: Hainan Sihuan Cardiovascular Drug Research Institute Co.,Ltd. Patentee before: JILIN HUIKANG PHARMACEUTICAL Co.,Ltd. |